Hemophilia Treatment Market Research Report - Forecast to 2030

Hemophilia Treatment Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User Forecast Till 2030

ID: MRFR/Pharma/4233-CR | October 2018 | Region: Global | 158 Pages         

Hemophilia Treatment Market Speak to Analyst Request a Free Sample

Hemophilia Treatment Market

Hemophilia Treatment Market is expected to rise at a CAGR of 6.10%, with a significant value during the estimated the forecasting year of 2022-2030.

Segmentation
By Type Hemophilia A Hemophilia B Hemophilia C
By Treatment Recombinant Coagulation Factor Plasma-Derived Coagulation Factor Desmopressin Antifibrinolytic Agents
Key Players
Companies Profiled    F.Hoffmann-La Roche Ltd   Octapharma   CSL Behring   Kedrion    Sanofi   Bayer AG   Baxter   Swedish Orphan Biovitrum AB   Grifols International S.A   Shire
Drivers
Market Driving Forces   Increased prevalence of the disease    demand for various hemophilia treatment modules
Request a Free Sample

Hemophilia Treatment Market Overview:


The hemophilia treatment market is expected to rise at CAGR of 6.10% to reach USD 25.7 billion during the forecast period 2022-2030.


A bleeding disease category known as hemophilia is characterized by slow blood clotting. It primarily falls under the categories of hemophilia A, and hemophilia B. Hemophilia is typically handed down via families. Children that are male seem to inherit it the most. Bleeding is the hallmark sign of hemophilia. Mild instances are anticipated to go unnoticed until significant bleeding after surgery or an accident. In extreme situations, bleeding happens randomly. Anywhere can have internal bleeding, and bleeding into joints is frequent.


After a person experiences an unusual bleeding event, it is diagnosed. A blood test can also identify the issue if additional family members are affected. The main course of therapy involves injecting blood through a vein with an extra clotting factor. Certain precautions must be followed during surgery if you suffer from this bleeding problem. Therefore, the patient's surgeon must know this problem before performing. Sharing information about the problem with blood relations is crucial since they could get the condition.


The rise in hemophilia prevalence, improvements in treatment technology, and supportive governmental activities for hemophilia management are all contributing factors to the market share growth for hemophilia treatments.


COVID 19 Analysis: 


The outbreak of COVID 19 has affected a huge population all over the globe. However, the people who are diagnosed with Hemophilia are very much prone to infectious diseases. Period before COVID also, the blood-borne viruses have severely targeted the Hemophilia patients. Hemophilia patients are advised to monitor their blood pressure and follow medical guidelines to ensure a good immune system. Hence the pandemic has increased the Hemophilia Treatment market value. 


In December 2020, four associations namely the World Federation of Hemophilia (WFH), the European Association for Hemophilia and Allied Disorders (EAHAD), European Hemophilia Consortium (EHC), and U.S. National Hemophilia Foundation (NHF) have combined and issued COVID vaccination guidelines for the Hemophilia patients which have also recommended to continue the treatment for Hemophilia after the COVID vaccination. Such constant guidance and recommendations have enhanced the Hemophilia Treatment market outlook during the pandemic. 


Market dynamics: 


Market drivers:


The increasing number of Hemophilia cases across the globe has been the primary factor that fuels the Hemophilia Treatment industry growth. In the year 2019, there were over 49,083 people diagnosed with bleeding disorders which have increased to 400,000 people in the year 2020-2021. Additionally, favorable government schemes in several countries like reducing the expenditure related to Hemophilia Treatment have impacted the market growth. 


The varied availability of therapies and medications has increased the demand for the Hemophilia Treatment market growth. Therapy of inhibitors, home therapy, free factor replacement, Antifibrinolytic medicines, gene therapy, and physical therapy are some of the commonly utilized therapies and medications used in Hemophilia treatment. These factors have created a huge positive impact on the Hemophilia Treatment market growth. 


Market opportunities: 


The increasing governmental schemes and aggressive campaigning has aided the growth of the Hemophilia Treatment market in recent years. Especially the medical guidelines according to the COVID vaccination has enhanced the treatment and facilities related to Hemophilia Treatment in recent years. The injectable administration is showcasing a growth rate of over 5% in recent years, owing to the increased life quality and enhance overall treatment witnessed in Hemophilia patients. 


The recent technologies and medications have created a revolution in the Hemophilia Treatment market outlook in recent years. Recent inventions have shown up to 80% of recovery from the symptoms of the condition and over 94% reduction in the annual bleeding rates. These factors have created a major opportunity for the Hemophilia Treatment industry growth. 


Market restraints: 


The higher costs associated with the recombinant products and the complications involved in the replacement therapies are currently hindering the growth of the Hemophilia Treatment industry.


Hemophilia patients who undergo the replacement therapies acquire complications like viral infections like hepatitis B and C or HIV. These adverse actions on treating the condition have impacted the growth of the Hemophilia Treatment industry.


The patients are capable of developing inhibitors that destroy the injected clotting factor before they start to work. The chances of developing these inhibitors in the patients with Severe Hemophilia A range between 20-30% and the chances in patients with hemophilia B ranges between 2-5%. These factors have also impacted the growth of the Hemophilia treatment industry. 


Market challenges: 


The increasing costs of the recombinant products and the overall treatment are considered as the primary challenge for the growth of Hemophilia treatment in recent years. The higher investment requirements in the R&D development and manufacturing processes are the primary reasons for the increasing costs of the treatment. 


Some of the therapies like gene therapy are yet to be approved for treating Hemophilia. The delays in the researches in the clinical trials are also imposing challenges for the growth of the Hemophilia Treatment market. 


Cumulative growth analysis: 


The recombinant coagulation factor concentrates have dominated the market with 52.91% in the year 2020. The growing research activities in gene therapies and various other methods are significantly increasing the demand for the Hemophilia Treatment market growth. The increasing government incentives towards the market and aggressive campaigns have also aided the growth of the Hemophilia Treatment industry. 


The Hemophilia Treatment industry registering a CAGR of 6.10% in the forecast period. The rising number of cases where bleeding occurs in joints has impacted the growth of the market in recent years. Joint bleeding is considered the major challenge in the market, owing to the higher chances of permanent damage of knee, ankle, or elbow joints. The development of inhibitors that slashes the efficacy of administrating drugs and medications is also becoming a major challenge in the Hemophilia Treatment industry in recent years. 


Value chain analysis: 


Hemophilia is a bleeding disorder that occurs if the individual’s blood clotting mechanism is damaged. The recent reports state that one in 5000 males are born with Hemophilia in the US, however, the poor economic condition of the country highly affects the treatment and access to the facility. A recent study shows that over 75% of Hemophilia patients are unable to access the treatments, due to which over 60% of patients are developing severity of the condition.  


Increasing awareness towards home therapies, effective precautions, and physical therapies have reduced the severity of the condition in several Hemophilia cases. Additionally, the inventions in the treatments and methodologies have increased the Hemophilia treatment market value in recent years. 


Segment overview: 


Based on diagnosis: 



Based on treatment: 



  • Plasma-derived coagulation factor concentrate

  • Recombinant Coagulation Factor Concentrates

  • Desmopressin

  • Antifibrinolytic agents

  • Gene therapy 


Based on the product: 



  • Plasma-derived coagulation factor concentrates





      • Factor VIII

      • Factor IX

      • Factor XIII

      • Activated Prothrombin complex concentrate

      • Von Willebrand factor



  • Recombinant coagulation factor concentrates



      • Factor VIII

      • Factor IX

      • Von willebrand factor



  • Desmopressin

  • Antifibrinolytic agents 


Based on distribution channel:



  • Hospital pharmacy

  • Retail pharmacy

  • Others 


Regional analysis: 


Currently, North America is handling the Hemophilia treatment strategies better by increasing its partnerships and collaborations with leading market players. These strategies have impacted the market growth positively. Additionally, increasing awareness of the condition and the technological advances in the products and therapeutic methods have further fueled the growth of the Hemophilia treatment market in recent years in North America. 


Association of America has expanded its market growth by offering co-pay initiatives for the patients to acquire continuous treatment. Recently, the advancements in gene therapy that targets coagulation factors have impacted a huge impact on the Hemophilia treatment industry. Asia-pacific is expected to hold the second-largest position in the Hemophilia Treatment market outlook because of the increasing favorable reimbursement policies. Stats of China has declared that over 80% of the Hemophilia treatment done in the region has been covered under health insurance which accounted for more than USD 16,000 in the year 2012. Since then the favorable schemes have been rising in China. 


Competitive landscape: 



  • Takeda Pharmaceutical Co., Ltd.,

  • Sanofi S.A., Octapharma AG

  • Swedish Orphan Biovitrum AB

  • Baxter International Inc.

  • Biogen Inc.

  • Bayer AG

  • CSL Behring

  • Ferring B.V.

  • Pfizer, Inc.

  • Kedrion

  • Novo Nordisk A/S

  • F. Hoffmann-La Roche AG. 


Recent developments: 



  • The increase also influences the growth of the Hemophilia Treatment Market in research and development studies on treatment treatments in the sector, the target population, the rate of diagnosis, and the usage of preventive therapy for hemophilia.

  • However, the market expansion is anticipated to be constrained by the high cost of hemophilia treatment, a shortage of hemophilia medications, and significant side effects linked to plasma-derived products.

  • On the other hand, the increased knowledge of hemophilia in emerging nations offers the hemophilia treatment business a chance to expand.


Report overview: 


This report has covered: 



  • Market overview

  • COVID -19 Analysis

  • Market dynamics

  • Cumulative growth analysis

  • Value chain analysis

  • Segment overview

  • Regional analysis

  • Competitive landscape

  • Recent developments 


Segmentation Table: 


Based on diagnosis: 



  • Replacement therapy

  • Gene Therapy 


Based on treatment: 



  • Plasma-derived coagulation factor concentrate

  • Recombinant Coagulation Factor Concentrates

  • Desmopressin

  • Antifibrinolytic agents

  • Gene therapy 


Based on the product: 



  • Plasma-derived coagulation factor concentrates





      • Factor VIII

      • Factor IX

      • Factor XIII

      • Activated Prothrombin complex concentrate

      • Von Willebrand factor



  • Recombinant coagulation factor concentrates



      • Factor VIII

      • Factor IX

      • Von willebrand factor



  • Desmopressin

  • Antifibrinolytic agents 


Based on distribution channel:



  • Hospital pharmacy

  • Retail pharmacy

  • Others



Report Scope:

Report Attribute/Metric Details
  Market Size   2030:USD 25.7 billion
  CAGR   6.10% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F.Hoffmann-La Roche Ltd, Octapharma, CSL Behring, Kedrion, Sanofi, Bayer AG, Baxter, Swedish Orphan Biovitrum AB, Grifols International S.A, Shire, Pfizer Inc, and Novo Nordisk A/S.
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions, new product developments
  Key Market Drivers   Increased prevalence of the disease has fueled the demand for various hemophilia treatment modules


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Global Hemophilia Treatment Market was valued at USD 25.7 billion in 2030.

The market is expected to exhibit a strong 6.10% CAGR over the forecast period from 2022 to 2030.

Leading players in the Hemophilia Treatment Market include Octapharma, Sanofi, and Bayer, among others.

The leading type of hemophilia is hemophilia A, which held a share of 78.7% in the market in 2017.

Growing advances in recombinant cell development are likely to be a major driver for the Hemophilia Treatment Market.